The long-awaited alternative to Coumadin (warfarin) has just been approved by the United States Food and Drug Administration. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation (afib) for preventing afib-related strokes.
The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn't require the monitoring nor the restrictive diet that warfarin does.
Learn more at:
FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation
Add a Comment1 Comments
I took one150mg tablet per day for a month w/o any adverse reactions. I now have a prescription based on that and want to continue that same dosage but the manufacturers recommended dosage is 2 tablets per day. As a patient with two previous periods of Atrial Fib, will I not be relatively safe from clotting compared to the last seven years with just Plavix and baby aspirin. I am taking 2 tablets of Sotalol per day and wish to avoid further side affects.
February 8, 2011 - 11:21pmThis Comment